Video

Specialty Pharmacy and the Affordable Care Act

Author(s):

Davy James, Managing Editor

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the impact of the Affordable Care Act on specialty pharmacy.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the impact of the Affordable Care Act on specialty pharmacy.

This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.

Related Videos
Pharmacist helping a patient with medication -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
Patient receiving cancer treatment infusion -- Image credit: UlrikaArt | stock.adobe.com
Related Content
Schizophrenia
April 1st 2025

Use of Long-Acting Injectable Antipsychotic Medications in Schizophrenia Treatment

Angie Oster, PharmD Cara Colodonato, PharmD
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Exploring the Tumor Microenvironment Interactions Between Cancer Cells, TCells, and Nanoparticles in Cancer Therapy and Immunology
March 31st 2025

NCCN 2025: Managing Immune Checkpoint Inhibitor-Related Toxicities in Cancer Care

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
X-ray image of liver -- Image credit: Sebastian Kaulitzki | stock.adobe.com
March 31st 2025

BEAM-302 Receives FDA IND Clearance for AATD, a Genetic Disorder Affecting the Liver and Lungs

Gillian McGovern, Associate Editor
Gene therapy innovation for hemophilia treatment - scientific visualization for medical research
March 28th 2025

FDA Approves Fitusiran For Prophylactic Hemophilia A, B Treatment Regardless of Inhibitor Status

Luke Halpern, Assistant Editor